157 related articles for article (PubMed ID: 36929572)
1. Leveraging homologous recombination repair deficiency in sarcoma.
Slade D; Loizou JI
EMBO Mol Med; 2023 Apr; 15(4):e17453. PubMed ID: 36929572
[TBL] [Abstract][Full Text] [Related]
2. Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma.
Planas-Paz L; Pliego-Mendieta A; Hagedorn C; Aguilera-Garcia D; Haberecker M; Arnold F; Herzog M; Bankel L; Guggenberger R; Steiner S; Chen Y; Kahraman A; Zoche M; Rubin MA; Moch H; Britschgi C; Pauli C
EMBO Mol Med; 2023 Apr; 15(4):e16863. PubMed ID: 36779660
[TBL] [Abstract][Full Text] [Related]
3. Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective.
Herzog TJ; Vergote I; Gomella LG; Milenkova T; French T; Tonikian R; Poehlein C; Hussain M
Eur J Cancer; 2023 Jan; 179():136-146. PubMed ID: 36563604
[TBL] [Abstract][Full Text] [Related]
4. Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors.
Paulet L; Trecourt A; Leary A; Peron J; Descotes F; Devouassoux-Shisheboran M; Leroy K; You B; Lopez J
Eur J Cancer; 2022 May; 166():87-99. PubMed ID: 35279473
[TBL] [Abstract][Full Text] [Related]
5. Homologous Recombination Repair Deficiency: An Overview for Pathologists.
Doig KD; Fellowes AP; Fox SB
Mod Pathol; 2023 Mar; 36(3):100049. PubMed ID: 36788098
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic targeting of DNA damage repair pathways guided by homologous recombination deficiency scoring in ovarian cancers.
Lin C; Liu P; Shi C; Qiu L; Shang D; Lu Z; Tu Z; Liu H
Fundam Clin Pharmacol; 2023 Apr; 37(2):194-214. PubMed ID: 36130021
[TBL] [Abstract][Full Text] [Related]
7. Homologous recombination repair deficiency as a therapeutic target in sarcoma.
Oza J; Doshi SD; Hao L; Musi E; Schwartz GK; Ingham M
Semin Oncol; 2020 Dec; 47(6):380-389. PubMed ID: 33183763
[TBL] [Abstract][Full Text] [Related]
8. Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
Tymon-Rosario JR; Manara P; Manavella DD; Bellone S; Hartwich TMP; Harold J; Yang-Hartwich Y; Zipponi M; Choi J; Jeong K; Mutlu L; Yang K; Altwerger G; Menderes G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Schwartz PE; Alexandrov LB; Santin AD
Gynecol Oncol; 2022 Jul; 166(1):117-125. PubMed ID: 35599167
[TBL] [Abstract][Full Text] [Related]
9. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
10. 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
Hurley RM; Wahner Hendrickson AE; Visscher DW; Ansell P; Harrell MI; Wagner JM; Negron V; Goergen KM; Maurer MJ; Oberg AL; Meng XW; Flatten KS; De Jonge MJA; Van Herpen CD; Gietema JA; Koornstra RHT; Jager A; den Hollander MW; Dudley M; Shepherd SP; Swisher EM; Kaufmann SH
Gynecol Oncol; 2019 Apr; 153(1):127-134. PubMed ID: 30686551
[TBL] [Abstract][Full Text] [Related]
11. Patient Assessment and Therapy Planning Based on Homologous Recombination Repair Deficiency.
Li W; Gao L; Yi X; Shi S; Huang J; Shi L; Zhou X; Wu L; Ying J
Genomics Proteomics Bioinformatics; 2023 Oct; 21(5):962-975. PubMed ID: 36791952
[TBL] [Abstract][Full Text] [Related]
12. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
13. Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors.
Mekonnen N; Yang H; Shin YK
Front Oncol; 2022; 12():880643. PubMed ID: 35785170
[TBL] [Abstract][Full Text] [Related]
14. Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas.
Li H; Tu J; Zhao Z; Chen L; Qu Y; Li H; Yao H; Wang X; Lee DF; Shen J; Wen L; Huang G; Xie X
Theranostics; 2020; 10(21):9477-9494. PubMed ID: 32863940
[No Abstract] [Full Text] [Related]
15. Homologous recombination deficiency and ovarian cancer.
Ledermann JA; Drew Y; Kristeleit RS
Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
[TBL] [Abstract][Full Text] [Related]
16. Homologous recombination proficiency in ovarian and breast cancer patients.
Creeden JF; Nanavaty NS; Einloth KR; Gillman CE; Stanbery L; Hamouda DM; Dworkin L; Nemunaitis J
BMC Cancer; 2021 Oct; 21(1):1154. PubMed ID: 34711195
[TBL] [Abstract][Full Text] [Related]
17. [Homologous recombination repair deficiency as a predictive biomarker : Basic mechanisms and detection methods].
Pfarr N; Merkelbach-Bruse S
Pathologe; 2021 Jul; 42(4):391-398. PubMed ID: 34152463
[TBL] [Abstract][Full Text] [Related]
18. The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
Rimar KJ; Tran PT; Matulewicz RS; Hussain M; Meeks JJ
Cancer; 2017 Jun; 123(11):1912-1924. PubMed ID: 28323334
[TBL] [Abstract][Full Text] [Related]
19. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
Lau CH; Seow KM; Chen KH
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
[TBL] [Abstract][Full Text] [Related]
20. Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.
Kim DS; Camacho CV; Kraus WL
Exp Mol Med; 2021 Jan; 53(1):42-51. PubMed ID: 33487630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]